[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100135545":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":40,"collaborators":42,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Stanford University","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"James M Ford","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Meredith Mills","CONTACT","(650) 724-5223","bluett@stanford.edu",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Stanford University School of Medicine","RECRUITING","Stanford","California","94305","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-122.16608,37.42411,{"lat":31,"lon":30},[34,36,37],{"name":14,"role":15,"phone":35,"phoneExt":7,"email":17},"650-724-5223",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":38,"role":39,"phone":7,"phoneExt":7,"email":7},"Allison Walsh Kurian","SUB_INVESTIGATOR",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[43,45],{"name":44,"class":6},"Breast Cancer Research Foundation",{"name":46,"class":6},"Susan G. Komen Breast Cancer Foundation","100135545","genetic--pathological-studies-of-brca1brca2-associated-tumors--blood-samples-100135545",false,"NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples","Inclusion Criteria:\n\nI. Women who have a high risk of developing breast or ovarian cancer due to a known germline mutation in the BRCA1\u002F2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong family history of either breast or ovarian cancer, in the absence of known cancer susceptibility gene mutation.\n\nII. Women who are approaching surgery for resection of a pelvic mass, which is considered suspicious for neoplasia by radiologic or clinical criteria; such women may or may not also meet criteria for inclusion in group I.","FEMALE","18 Years",{"count":56,"type":57},3300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.",[61,62,63,64],"Breast Cancer","Ovarian Cancer","Gynecologic Cancers","Ovarian\u002FPeritoneal\u002FFallopian Cancer",[66],"quality of life","2026-05-14",{"date":69,"type":70},"2026-05-18","ACTUAL",{"date":72,"type":7},"2001-08",{"date":74,"type":57},"2099-01",{"name":5,"class":6},1]